Company Overview
Schrödinger, Inc. operates by developing a physics-based computational platform designed to facilitate the discovery of novel molecules for drug development and materials applications across the United States, Asia-Pacific, Europe, the Middle East, Africa, and international markets. This operational focus situates the firm within the Healthcare sector, specifically the Health Information Services industry, where it leverages advanced computational chemistry to solve complex biological and physical problems. The company maintains a substantial scale with a market capitalization of $885.16M, an annual revenue of $255.87M, and a workforce comprising 850 employees. These valuation and revenue figures indicate that Schrödinger, Inc. holds a significant position as a major player in the computational biology space, possessing the capitalization and human resources necessary to compete in high-growth technological sectors while maintaining a robust operational footprint globally.
Financial Health
Schrödinger, Inc. reported a trailing twelve-month revenue of $255.87M, yet the company recorded a net income of $-103,265,000 and an EBITDA of $-160,874,000, revealing a substantial gap between top-line generation and bottom-line profitability that highlights a heavy cost structure or significant investment in R&D and operational expansion. Despite the reported net losses, the company demonstrated strong operational liquidity with a free cash flow of $99.98M, which provides a critical buffer for financial flexibility and allows the firm to fund operations or strategic initiatives without immediate reliance on external capital markets. The company's margin profile presents a complex picture, with a gross margin of 55.7% indicating efficient production or service delivery relative to sales, contrasted by an operating margin of -19.7% and a profit margin of -40.4% that suggest high overhead costs or non-operating expenses are eroding bottom-line returns. On the balance sheet, the company holds $395.46M in cash against $109.31M in debt, resulting in a debt-to-equity ratio of 30.03, which suggests a leveraged capital structure where equity financing plays a more dominant role than debt obligations. This capital position is supported by a current ratio of 2.75, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities, thereby ensuring strong short-term liquidity. Furthermore, the return metrics reflect the current financial reality, with a return on equity of -26.3% and a return on assets of -13.5%, signaling that management is currently deploying capital to generate losses rather than positive returns, likely in pursuit of long-term strategic growth objectives.
Valuation Assessment
Valuation multiples for Schrödinger, Inc. reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -8.69, implying that the market expects earnings to remain negative or turn negative in the near term rather than anticipating an immediate earnings turnaround. The price-to-book ratio stands at 2.43, indicating that the market values the company at a significant premium over its book value, which often occurs in technology and biotech firms where intangible assets and intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 3.46 and an EV/EBITDA of -3.74 suggest that investors are pricing the company based on revenue generation potential and market share rather than current earnings power, a common practice for early-stage growth companies. The stock has exhibited significant price volatility over the past year, trading between a 52-week low of $11.11 and a 52-week high of $27.63, meaning the current price sits at a level that reflects the uncertainty surrounding its path to profitability. The stock's beta of 1.65 indicates that the company's share price is 65% more volatile than the broader market, suggesting that SDGR will experience amplified swings in price during periods of market stress or sector-specific developments.
Growth & Income
Schrödinger, Inc. experienced a revenue growth of -1.2% year-over-year, while earnings growth is listed as N/A due to the company's lack of profitability, implying that top-line contraction is currently outpacing any potential for earnings improvement or that the company is still in a phase where revenue metrics are the primary focus over earnings per share. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, effectively allocating all available cash flow toward reinvestment in the business rather than returning capital to shareholders. This reinvestment strategy is consistent with companies in the Health Information Services industry that prioritize funding research and development to sustain long-term competitiveness over providing immediate income to investors. The overall growth and income profile for Schrödinger, Inc. is characterized by a contraction in revenue alongside negative earnings, with no dividend income to offset these fundamental challenges, presenting a high-risk, high-reward scenario dependent entirely on the company's ability to pivot toward profitability.